In the phase II BOVen trial, patients with untreated TP53-mutated MCL were treated with a combination of zanubrutinib, venetoclax, and obinutuzumab for a minimum of 24 cycles, based on minimal residual disease (MRD) status. Here, TP53 is linked to mantle cell lymphoma.